RT Journal Article
T1 Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.
A1 Torrens, Gabriel
A1 Cabot, Gabriel
A1 Ocampo-Sosa, Alain A
A1 Conejo, M Carmen
A1 Zamorano, Laura
A1 Navarro, Ferran
A1 Pascual, Alvaro
A1 Martinez-Martinez, Luis
A1 Oliver, Antonio
K1 Azabicyclo Compounds
K1 Drug Combinations
K1 Meropenem
K1 Pseudomonas aeruginosa
K1 beta-Lactam Resistance
AB The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at ≤4 μg/ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant β-lactam resistance mechanisms.
PB American Society for Microbiology
YR 2016
FD 2016-09-23
LK http://hdl.handle.net/10668/10328
UL http://hdl.handle.net/10668/10328
LA en
NO Torrens G, Cabot G, Ocampo-Sosa AA, Conejo MC, Zamorano L, Navarro F, et al. Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6407-10.
DS RISalud
RD Apr 13, 2025